Infliximab for 6 months added on combination therapy in early rheumatoid arthritis – 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study) - UTU Research Portal

A1 Refereed original research article in a scientific journal

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis – 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)

Subtitle: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)

Authors: Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppanen O, Luosujarvi R, Luukkainen R, Karjalainen A, Blafield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Mottonen T

Publisher: BMJ PUBLISHING GROUP

Publication year: 2013

Journal: Annals of the Rheumatic Diseases

Journal name in source: ANNALS OF THE RHEUMATIC DISEASES

Journal acronym: ANN RHEUM DIS

Number in series: 6

Volume: 72

Issue: 6

First page : 851

Last page: 857

Number of pages: 7

ISSN: 0003-4967

DOI: https://doi.org/10.1136/annrheumdis-2012-201365

Abstract

Conclusions Most patients with early active RA achieve clinical remission and develop negligible joint damage with the intensified FIN-RACo regimen. Adding INFL for the first 6 months delays radiological progression.